In our study, we demonstrated that sunitinib induces PIM-1 expression and that inhibition of PIM kinase activity with SGI-1776 significantly enhanced the efficacy of sunitinib in both in vitro and in vivo models of RCC. The gene discussed is PIM1; the disease is renal cell carcinoma.